The estimated Net Worth of Daniel Orlando is at least $2.54 Million dollars as of 10 May 2018. Daniel Orlando owns over 68,360 units of Vericel Corp stock worth over $2,542,947 and over the last 10 years Daniel sold VCEL stock worth over $0.
Daniel has made over 1 trades of the Vericel Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently Daniel exercised 68,360 units of VCEL stock worth $224,904 on 10 May 2018.
The largest trade Daniel's ever made was exercising 68,360 units of Vericel Corp stock on 10 May 2018 worth over $224,904. On average, Daniel trades about 8,545 units every 0 days since 2015. As of 10 May 2018 Daniel still owns at least 58,191 units of Vericel Corp stock.
You can see the complete history of Daniel Orlando stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel, and Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Vericel Corp executives and other stock owners filed with the SEC include: